REG-Mydecine Innovations Group Inc: Management cease trade order

Mydecine InnovationsAnnouncement

03/05/2024 07:15

MYDECINE RECEIVES MANAGEMENT CEASE TRADE ORDER

VANCOUVER, British Columbia, 3 May 2024- Mydecine Innovations Group Inc. (the
"Company") (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it
has received a temporary Management Cease Trade Order ("MCTO") on April 26,
2024, under National Policy 12-203 - Management Cease Trade Orders ("NP
12-203") from the British Columbia Securities Commission ("BCSC") in
connection with the Company's filing of its audited annual financial
statements and MD&A for the financial year ended December 31, 2023.

Pursuant to the MCTO, the chief executive officer and the chief financial
officer of the Company may not trade in securities of the Company until such
time as the Company files its annual audited financial statements for the year
ended December 31, 2023, management's discussion and analysis, and related
certifications (the "Required Documents") and the BCSC revokes the MCTO. The
MCTO does not affect the ability of shareholders to trade their securities.

The Company's board of directors and management confirm that they are working
expeditiously to file the Required Documents and confirm that since the
Company's press release at 7:00AM May 3, 2024, there is no other material
information respecting the Company's affairs that has not been generally
disclosed.  The audited annual financial statements for December 31, 2023
will include December 31, 2022 restated comparatives.

Until the Required Documents have been filed, the Company intends to continue
to satisfy the provisions of the alternative information guidelines specified
in NP 12-203 by issuing biweekly default status reports in the form of further
press releases for so long as the Company remains in default of the financial
statement filing requirement.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

On behalf of the Board of Directors

MYDECINE INNOVATIONS GROUP INC.

Joshua Bartch
Chief Executive Officer
contact@mydecineinc.com

AQSE Corporate Advisor

Novum Securities Limited  Tel: +44 (0)207 399 9400

David Coffman/ George Duxberry

About Mydecine Innovations Group Inc.

Mydecine Innovations Group™ is a biotechnology company developing the next
generation of innovative medications and therapies to address mental health
disorders such as nicotine addiction and posttraumatic stress disorder (PTSD).
The core strategy blends advanced technology with an elaborate infrastructure
for drug discovery and development. Mydecine's dedicated multinational team
constantly develops new paths for breakthrough treatment solutions in areas
with considerable unmet needs. By collaborating with some of the world's
leading specialists, the Company aspires to responsibly speed up the
development of breakthrough medications to provide patients with safer and
more effective treatment solutions. At the same time, Mydecine's approach
focuses on the next generation of psychedelic medicine by creating innovative
compounds with unmatched therapeutic potential through its clinical trial
efforts with world-class scientific and regulatory expertise.

Learn more at: https://www.mydecine.com/ and follow the company on Twitter,
LinkedIn, YouTube, and Instagram.

Forward-looking Information Statement

This news release may contain certain "forward-looking statements" and
"forward-looking information" within the meaning of applicable Canadian and
United States securities laws. When used in this news release, the words
"anticipate", "believe", "estimate", "expect", "target, "plan", "forecast",
"may", "schedule" and other similar words or expressions identify
forward-looking statements or information. These forward-looking statements or
information may relate to the anticipated timing for the filing of the Annual
Filings, and other factors or information. Such statements represent the
Company's current views with respect to future events and are necessarily
based upon a number of assumptions and estimates that, while considered
reasonable by the Company, are inherently subject to significant business,
economic, competitive, political and social risks, contingencies and
uncertainties. Many factors, both known and unknown, could cause results,
performance or achievements to be materially different from the results,
performance or achievements that are or may be expressed or implied by such
forward-looking statements. The Company does not intend, and does not assume
any obligation, to update these forward-looking statements or information to
reflect changes in assumptions or changes in circumstances or any other events
affections such statements and information other than as required by
applicable laws, rules and regulations.

 



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved